About This Webinar
Artificial intelligence (AI) and advanced technologies are rapidly transforming healthcare, offering new opportunities to improve diagnosis, risk assessment, treatment planning, and patient outcomes in Myelodysplastic Syndromes (MDS).
Webinar Date: April 7, 2026
Webinar Time: 12:00 - 1:30 p.m. ET
Featured Speakers:
Matteo Della Porta, MD, is Head of the Leukemia Unit at the Cancer Center of Humanitas Research Hospital and Full Professor of Hematology at Humanitas University in Milan, Italy. He also serves as Head of the Center for Accelerating Leukemia/Lymphoma Research (CALR) at the Humanitas AI Center, a multidisciplinary center dedicated to advancing research and innovation in hematologic malignancies through cutting-edge technologies.
His research focuses on the integration of clinical investigation, genomics, and Artificial Intelligence in hematology. His primary scientific interests include the development and validation of AI-driven models for prognostic stratification and precision medicine, the design and implementation of clinical Decision Support Systems, the genomics of hematologic neoplasms, and the translation of innovative, personalized medicine strategies into clinical practice to improve diagnosis, risk assessment, and therapeutic decision-making in patients with myeloid and lymphoid malignancies.
Saverio D’Amico is the CEO and co-founder of Train, a spin-off of the IRCCS Istituto Clinico Humanitas, specializing in the development of generative AI technologies in the healthcare sector, such as synthetic data generation and digital twins. Saverio is also a Team Leader at the Humanitas Hospital AI Center, where he works on AI solutions applied to healthcare and is actively involved in the European projects GenoMed4All, Synthema, and Synthia, which aim to use advanced AI technologies for personalized medicine. Always passionate about innovation and technology, Saverio holds a degree in Biomedical Engineering from the Politecnico di Milano. Thanks to a solid background in artificial intelligence, consolidated through his experience in management consulting, he has contributed to the development of numerous strategic and innovation projects.
About This Webinar
Artificial intelligence (AI) and advanced technologies are rapidly transforming healthcare, offering new opportunities to improve diagnosis, risk assessment, treatment planning, and patient outcomes in Myelodysplastic Syndromes (MDS).
Webinar Date: April 7, 2026
Webinar Time: 12:00 - 1:30 p.m. ET
Featured Speakers:
Matteo Della Porta, MD, is Head of the Leukemia Unit at the Cancer Center of Humanitas Research Hospital and Full Professor of Hematology at Humanitas University in Milan, Italy. He also serves as Head of the Center for Accelerating Leukemia/Lymphoma Research (CALR) at the Humanitas AI Center, a multidisciplinary center dedicated to advancing research and innovation in hematologic malignancies through cutting-edge technologies.
His research focuses on the integration of clinical investigation, genomics, and Artificial Intelligence in hematology. His primary scientific interests include the development and validation of AI-driven models for prognostic stratification and precision medicine, the design and implementation of clinical Decision Support Systems, the genomics of hematologic neoplasms, and the translation of innovative, personalized medicine strategies into clinical practice to improve diagnosis, risk assessment, and therapeutic decision-making in patients with myeloid and lymphoid malignancies.
Saverio D’Amico is the CEO and co-founder of Train, a spin-off of the IRCCS Istituto Clinico Humanitas, specializing in the development of generative AI technologies in the healthcare sector, such as synthetic data generation and digital twins. Saverio is also a Team Leader at the Humanitas Hospital AI Center, where he works on AI solutions applied to healthcare and is actively involved in the European projects GenoMed4All, Synthema, and Synthia, which aim to use advanced AI technologies for personalized medicine. Always passionate about innovation and technology, Saverio holds a degree in Biomedical Engineering from the Politecnico di Milano. Thanks to a solid background in artificial intelligence, consolidated through his experience in management consulting, he has contributed to the development of numerous strategic and innovation projects.